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Brief Description: 
Activation-induced cytidine deaminase (AID), a DNA mutator enzyme, contributes to 
inflammation-associated carcinogenesis through its mutagenic activity. In the present study, 
taking advantage of the ability of AID to induce stepwise genetic aberrations, we established a 
novel model showing accumulation of genetic alterations in fetal hepatic progenitor cells 
progressed to liver tumors, including both hepatocellular carcinoma and cholangiocarcinoma. We 
also revealed the overall landscape of genetic alterations accumulated during tumorigenesis by 
whole exome sequencing. 
3 
 
Financial Support: This work was supported by JSPS KAKENHI, Research program of the 
Project for Development of Innovative Research on Cancer Therapeutics (P-Direct) from 
Ministry of Education, Culture, Sports, Science and Technology of Japan, Health and Labour 
Sciences Research Grants for Research from the Ministry of Health, Labour and Welfare, and 
Takeda Science Foundation. 
 
Conflict of Interest 




















Activation-induced cytidine deaminase (AID) contributes to inflammation-associated 
carcinogenesis through its mutagenic activity. In the present study, by taking advantage of the 
ability of AID to induce genetic aberrations, we investigated whether liver cancer originates from 
hepatic stem/progenitor cells that accumulate stepwise genetic alterations. For this purpose, 
hepatic progenitor cells enriched from the fetal liver of AID transgenic (Tg) mice were 
transplanted into recipient “toxin-receptor mediated conditional cell knockout” (TRECK) mice, 
which have enhanced liver regeneration activity under the condition of diphtheria toxin treatment. 
Whole exome sequencing was used to determine the landscape of the accumulated genetic 
alterations in the transplanted progenitor cells during tumorigenesis. Liver tumors developed in 7 
of 11 (63.6%) recipient TRECK mice receiving enriched hepatic progenitor cells from AID Tg 
mice, while no tumorigenesis was observed in TRECK mice receiving hepatic progenitor cells of 
wild-type mice. Histologic examination revealed that the tumors showed characteristics of 
hepatocellular carcinoma and partial features of cholangiocarcinoma with expression of the AID 
transgene. Whole exome sequencing revealed that several dozen genes acquired single 
nucleotide variants in tumor tissues originating from the transplanted hepatic progenitor cells of 
AID Tg mice. Microarray analyses revealed that the majority of the mutations (>80%) were 
present in actively transcribed genes in the liver-lineage cells. These findings provided the 
evidence suggesting that accumulation of genetic alterations in fetal hepatic progenitor cells 
progressed to liver cancers, and the selection of mutagenesis depends on active transcription in 







Tumorigenesis comprises multiple processes with a stepwise accumulation of genetic alterations 
that drive the progressive transformation of normal cells into highly malignant derivatives 1.  
Recent studies of a large number of genomes in human cancer tissues clarified that cancer cells 
generally possess hundreds of somatic mutations and dysregulated gene expression profiles 2-4. 
Although the origin of cancer cells remains mostly unsolved at present, it might be difficult for 
fully differentiated cells to acquire these large numbers of nucleotide alterations during their 
limited life span to achieve malignant transformation. In contrast, stem/progenitor cells have a 
long lifetime in order to supply the differentiated progenies in each organ. Thus, it appears 
reasonable to assume that long-lived tissue stem/progenitor cells can accumulate genetic 
alterations and hence could be the origin of tumor cells. Consistent with this hypothesis, a 
number of studies have provided evidence that the mutations would most likely result in 
expansion of the altered stem cells, perpetuating and increasing the chances of additional 
mutations, leading to malignant transformation 5-8.  
 
Several studies have provided evidence that hepatocellular carcinoma (HCC) might originate 
from hepatic stem/progenitor cells 9-12. A histologic study of clinical specimens also revealed that 
a substantial number of human HCC tissues have bipotential characteristics with coexpression of 
biliary and hepatocytic markers such as cytokeratin 7 (CK7), CK19, alpha-fetoprotein (AFP), 
and albumin 13, 14. Conversely, all cholangiocarcinoma tissues examined showed hepatocellular 
differentiation in part of the tumor and expression of hepatic progenitor cell markers 15. Findings 
from a recent study also suggested that human HCC could arise as a consequence of the 
dysregulated proliferation of hepatic progenitor cells when the TGF-β and IL-6 signaling 




Activation-induced cytidine deaminase (AID) can induce genetic alterations in human genome 
DNA sequences 17, 18. Under physiological condition, AID is expressed almost exclusively in B 
lymphocytes, and plays a critical role not only in class switch recombination but also in somatic 
hypermutation of immunoglobulin genes. We recently demonstrated that inflammatory 
stimulation triggers aberrant AID expression in epithelial cells and initiates and/or promotes 
oncogenic pathways by inducing genetic alterations in various tumor-related genes 19, 20. Indeed, 
AID expression is induced by proinflammatory cytokine stimulation and/or hepatitis C virus 
infection through NF-kB activation in hepatocytes 21, and the resultant AID upregulation leads to 
the accumulation of somatic mutations in TP53 and c-MYC genes, both of which are frequently 
mutated in human cancer tissues 21, 22. These findings suggest that aberrant AID production 
induced by chronic inflammation in the liver contributes to hepatocarcinogenesis via the 
accumulation of genetic aberrations in tumor-related genes 23. 
 
The fact that it usually takes over a year for AID transgenic (Tg) mice to accumulate the genetic 
aberrations required for carcinogenesis 24, 25 prompted us to speculate that constitutive expression 
of AID in the cells with long life-span might possess the higher risk for malignant transformation 
compared to that in the cells with the limited life-span. Therefore, in the present study, we took 
advantage of the AID-mediated stepwise genotoxicity that recapitulates human 
hepatitis-associated carcinogenesis to investigate whether liver cancer originates from fetal 
hepatic progenitor cells with constitutive AID expression. Accordingly, we separated hepatic 
progenitor cells enriched from the fetal liver of AID Tg mice followed by transplantation into 
recipient mice and examined whether recipient mice receiving AID-expressing hepatic 
progenitor cells develop liver tumors. Furthermore, to unveil the overall landscape of genetic 
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alterations that accumulate in hepatic progenitor cells during the process of malignant 
transformation, we applied whole exome sequencing and determined the whole picture of genetic 
aberrations that accumulated in liver cancer cells originating from hepatic stem/progenitor cells. 
 
Materials and Methods 
Animals 
The “toxin-receptor mediated conditional cell knockout” mice, which are homozygous for the 
albumin enhancer/promoter driven-human heparin binding epidermal growth factor-like growth 
factor (hHB-EGF) alleles, achieve the specific and conditional ablation of hepatocytes under the 
treatment of diphtheria toxin (DT) 26. AID Tg mice were previously described 24. All animals 
were maintained in a specific pathogen-free facility at the Kyoto University Faculty of Medicine. 
All animal experiments were approved by the ethics committee for animal experiments and 
performed under the Guidelines for Animal Experiments of Kyoto University. 
 
Isolation of enriched hepatic progenitor cells, cell transplantation, and administration of 
diphtheria toxin 
Hepatic progenitor cells were obtained from the fetal liver of pregnant wild-type, AID Tg , and 
green fluorescent protein (GFP) Tg mice on gestational day 13.5 and were enriched through 
sphere formation as previously described 27. Briefly, after the digestion of fetal liver tissues using 
a 0.5% collagenase solution (Invitrogen, Carlsbad, CA), fetal liver cells were subjected to 
floating culture to form spheres in RPMI 1640 (Invitrogen) supplemented with 10% fetal calf 
serum. After 16 h incubation, the formed spheres were selected by gravity sedimentation and 
inoculated on type-I collagen-coated culture plates (Asahi Glass, Co., Ltd., Chiba, Japan). After 
24 h of incubation, floating hematopoietic cells were removed by washing and adhered cells 
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were collected using trypsin-ethylenediaminetetraacetic acid (EDTA) solution (Sigma-Aldrich 
Co., Ltd., St. Louis, MO) for 3 min. The dissociated cells were counted and suspended in a 
Ca2+-free Hank’s balanced salt solution (Invitrogen) with fetal calf serum at a density of 5.0 x 
106 cells/ml as the enriched hepatic progenitor cells. To characterize the enriched hepatic 
progenitor cells, expression levels of fetal liver stem/progenitor markers, including albumin, AFP, 
DLK1, CK19, and CD133, were examined using both immunohistochemistry and RT-PCR. In 
addition, the lack of expression of the hematopoietic cell marker CD45 in sphere-derived hepatic 
progenitor cells was also confirmed by both immunostaining and RT-PCR. 
 
To achieve efficient engraftment of transplanted hepatic progenitor cells to livers of the recipient 
mice, we used TRECK mice as a liver-specific regeneration model 26. TRECK mice express DT 
receptor under control of the albumin promoter, and treatment with DT selectively and efficiently 
ablates the hepatocytes, resulting in enhanced liver regeneration and efficient colonization of 
transplanted hepatic progenitor cells 27. The enriched hepatic progenitor cells were transplanted 
into 7- to 9-wk old TRECK mice using an intrasplenic approach 27, 28. We injected 0.2 ml of a 
cell suspension containing 1.0 x 106 hepatic progenitor cells. The DT was purified as described 
previously 26 and a total of 75 ng/kg DT was administered by intraperitoneal injection into 
recipient mice twice a week for 25 wk from the day of cell transplantation.  
 
Whole exome capture and massively-parallel sequencing  
Massively-parallel sequencing was performed using the Illumina Genome Analyzer IIx (Illumina, 
San Diego, CA) as described 29. End-repair of DNA fragments, addition of adenine to the 3’ ends 
of DNA fragments, adaptor ligation, and PCR amplification were performed according to the 
instructions. Exome capture was performed according to the NimbleGen Arrays Users Guide 
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(Roche, Basal, Switzerland). The DNA library was hybridized to the custom designed 
NimbleGen Seq Cap arrays targeting a total of 17,089 genes, including 157,728 exons. These 
libraries were enriched independently using a minimal PCR amplification step of 18 cycles with 
Phusion High-Fidelity DNA polymerase. The concentration of enriched DNAs were measured 
by Quant-iT PicoGreen Reagent and Kits (Invitrogen) to make a working concentration of 10 nM. 
Cluster generation and sequencing was performed for 76 cycles on the Illumina Genome 
Analyzer IIx as described using the pair-end protocol and collecting 76 bases from each read 29. 
The obtained images were analyzed and base-called using GA pipeline software version 1.4 with 
the default settings provided by Illumina. All sequence reads were deposited in the DNA Data 
Bank of Japan Sequence Read Archive; accession number DRA000601. 
 
RNA preparation and hybridization to the microarray 
Total RNA was extracted from adult mice (12 wk old) liver tissues, bone marrow, and the fetal 
liver at day 13.5 of gestation using RNeasy Mini Kit (Qiagen, Valencia, CA). The details of the 
procedures for hybridization to the microarray were described previously 30. RNA amplification 
and labeling were performed according to the manufacturer’s instructions (Agilent Technologies, 
Palo Alto, CA). Array image acquisition and feature extraction were performed using an Agilent 
G2505C scanner with feature extraction software (Agilent Technologies). Microarray data were 








Semiquantitative reverse transcription PCR and quantitative real-time genomic and 
reverse transcription-PCR 
 
Histology and immunohistochemistry 
 




These procedures are described in Supplementary Materials and Methods 31-33. 
 
Results 
Enrichment of hepatic progenitor cells derived from fetal mouse liver 
Enriched hepatic progenitor cells were obtained from the fetal liver of wild-type, AID Tg and  
GFP Tg mice through the formation of cell spheres, and the dissociated cells were cultured, 
counted, and then transplanted into recipient mice (Figure 1A). To characterize the 
sphere-derived hepatic cells used for the transplantation procedure, we first examined the 
expression of various marker genes in the fetal liver of wild-type mice. Immunohistochemistry 
revealed that expression of both the liver cell marker albumin and the hematopoietic cell marker 
CD45 were detectable in the fetal liver tissues (Figure 1B). Cells expressing DLK1, a cell 
surface marker for hepatic stem/progenitor cells, comprised ~10% of the total cells of the fetal 
liver parenchyma (Supplementary Figure 2A). The enriched cell population specifically 
contained cells expressing the hepatocyte-lineage cell markers such as albumin and AFP, but no 
expression of CD45 was detectable in these sphere-forming cells (Figure 1C). In addition, we 
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confirmed that almost the entire enriched sphere-derived cell population expressed E-cadherin 
and DLK1, and a subset of those enriched cells expressed CK19 and CD133 (Supplementary 
Figure 2B). On the other hand, the floating cells that did not form spheres strongly expressed 
CD45 (Figure 1D). RT-PCR also revealed that the sphere-forming cells prepared for the 
transplantation procedure expressed albumin, AFP, DLK1, CK19, and CD133 transcripts, but not 
CD45 (Figure 1E). Similar results were obtained in the fetal liver of AID Tg mice (data not 
shown). These expression profiles of the collected sphere-derived cells were consistent with 
those found in previous studies 34 and indicated that the enriched cells derived from the fetal liver 
fully contained hepatic lineage progenitor cells.  
 
Efficient engraftment of transplanted hepatic progenitor cells in the recipient liver 
To enhance engraftment of the transplanted cells in the liver, we used TRECK mice as a 
liver-specific regeneration model. These mice express hHB-EGF precursor, which functions as a 
DT receptor, under the control of an albumin promoter, and thus the hepatocytes of these mice 
are selectively ablated by the administration of DT 26. We confirmed that the transcripts of 
hHB-EGF were specifically detectable in the liver of the TRECK mice (Figure 2A), and 
immunohistochemistry also revealed that hHB-EGF protein expression was present in the 
TRECK mouse liver tissues (Figure 2B). Serum alanine aminotransferase levels of a TRECK 
mouse were increased at 24 h after 75ng/kg of DT administration, peaked at 48 to 72 h, and 
subsequently returned to basal levels after 120 h (Figure 2C). After repeated trials, we found that 
twice-weekly DT administration maintained the sublethal liver injury, resulting in the 
constitutive hepatic regeneration process. Under these experimental conditions, DT-mediated 
ablation of hepatocytes in TRECK mice resulted in the expansion of cells expressing E-cadherin, 
EpCAM, and HNF4α accompanied by an increased number of the Ki67-positive cells, 
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suggesting enhanced proliferation activity of hepatocyte-lineage cells including hepatic 
progenitor cells and mature hepatocytes in the TRECK liver tissues (Figure 2D, and data not 
shown).  
 
To examine the repopulation of the transplanted cells in the recipient liver, the hepatic progenitor 
cells of the GFP Tg fetal livers obtained in a similar way were introduced into the TRECK mice, 
followed by the repeated DT administration. At day 7, the GFP-positive cells were observed as 
clusters, and at day 30 the cluster of the GFP-positive cells was large enough to view 
macroscopically (Figure 2E). Moreover, the cluster of hepatocytes derived from the transplanted 
GFP-positive enriched hepatic progenitor cells was detectable in the recipient liver even 90 days 
after the transplantation while no such cells were observed in the liver of mice without DT 
administration (Figure 2F). These findings indicated that the transplanted cells efficiently 
engrafted and continued to proliferate in the recipient livers treated with DT as time progressed.  
 
Transplanted hepatic progenitor cells with constitutive AID expression progressed to liver 
cancers. 
Next, the enriched hepatic progenitor cells from AID Tg mice were transplanted into 13 recipient 
(TRECK) mice, and the DT was administered to the recipient mice for 25wk. Two mice died in a 
week after transplantation, while the remaining 11 mice were viable and thus subjected to 
phenotypic analyses. We found that liver tumors developed in 7 of 11 (63.6%) recipient mice that 
received the enriched hepatic progenitor cells of the AID Tg mice 90 wk after cell transplantation 
(Figure 3A). Among them, four mice developed multiple tumors and three developed a single 
large nodule. On the other hand, none of the 13 recipient mice receiving hepatic progenitor cells 
from wild-type or GFP Tg mice showed tumorigenesis during the same observation period, while 
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only one mouse developed a tumor with the characteristics of lipoma. Moreover, all the five 
recipient mice examined that received the mature hepatocytes of adult AID Tg mice at 6 months 
of age showed no phenotypic changes in the liver tissues. Histologic examination revealed that 
all the tumors examined showed the characteristics of well-to-moderately differentiated HCC. 
Interestingly, one tumor showed not only the enhanced AFP expression but also the ductal 
formation of tumor cells accompanied by the expression of CK19, indicating the features of 
intrahepatic cholangiocarcinoma (ICC) (Figure 3B, upper and middle panel). In addition, partial 
positivity for MUC1 immunostaining in the tumor indicated that the tumor contained the 
mucin-producing area (data not shown). On the other hand, no histologic changes were observed 
in the non-tumorous region of liver tissues receiving the AID-expressing hepatic progenitor cells 
(Figure 3B, lower panel).  
 
To examine whether the cancers that developed in recipient mice liver were derived from the 
transplanted hepatic progenitor cells, we examined the expression of the AID Tg mice-specific 
transgene in three randomly selected tumors that developed in the recipient livers. Southern 
blotting analyses revealed strong signals of the AID transgene in the tumor tissues (Figure 3C). 
Weak signal of the AID transgene was also detected in the non-tumorous region, suggesting 
continuous engraftment of the transplanted hepatic progenitor-derived cells in the recipient 
mouse liver. In contrast, there were no detectable signals of the AID transgene in organs other 
than the liver of recipient mice, such as kidney, or in liver tissues of the TRECK mice without 
receiving the transplantation. Quantitative genomic PCR analyses also confirmed that all tumor 
tissues examined strongly expressed the AID transgene (Figure 3D). Moreover, the expression 
level of hHB-EGF in the tumor tissue was significantly lower than that in the surrounding 
non-tumorous liver tissue (Supplementary Figure 2C). These findings suggested that the 
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transplanted hepatic progenitor cells with constitutive AID expression achieved the malignant 
transformation and progressed to either HCC or cholangiocarcinoma.  
 
Landscape of genetic alterations accumulated in the transplanted hepatic progenitor cells 
during the process of malignant transformation. 
To unveil the landscape of genetic alterations that accumulated in the transplanted hepatic 
progenitor cells during the process of tumorigenesis, we determined the sequences of the whole 
exome in two independent liver cancers from two different recipient mice and the corresponding 
hepatic progenitor cells of the same AID Tg mice from which they originated (Table1). As a 
control, we also determined the whole exome sequences of the livers of their littermates with a 
wild-type phenotype. A total of 94.2% of the reads were properly aligned to the reference mouse 
genome and accordingly we obtained about 4.4 Gb of the aligned sequence data per sample on 
average after exome enrichment. 77.6% of the captured target exons were covered by 20X or 
more coverage depth read with a high quality genotype call. The variant filtering process is 
summarized in Supplementary Figure 1. We identified 24 (23 single nucleotide variants [SNVs] 
and 1 indel) and 162 (160 SNVs and 2 indels) somatic mutations in HCC#1 and HCC#2, of 
which the number of mutated genes with SNVs were 23 (HCC#1) and 105 (HCC#2), 
respectively (Table 2, and Supplementary Table 4). As shown in Supplementary Figure 2D, C/G 
to T/A substitution pattern was dominant, consistent with the previous finding that AID induces 
C/G to T/A transition into the genome 23, 24. The candidate variants were then validated by 
conventional direct population Sanger sequencing (Supplementary Figure 3), and we finally 
confirmed that 20 (HCC#1) and 87 (HCC#2) SNVs were nonsynonymous variants. Among them, 
there were no genes commonly mutated in both tumors. Interestingly, 19 of 23 (82.6% in 
HCC#1) and 80 of 105 (76.2% in HCC #2) genes with SNVs were those reported in human liver 
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cancer tissues (International Cancer Genome Consortium; http://www.icgc.org/). Although 
tumor-suppressor Trp 53 gene also acquired mutations in both tumors, the nucleotide alteration 
rate was less than 20%. Pathway analyses using the KEGG (Kyoto Encyclopedia of Genes and 
Genomes) database (http://www.genome.jp/kegg/) revealed that 11 (HCC#1) and 66 (HCC#2) 
genes were categorized into the well-known signaling pathways, including peroxisome 
proliferator-activated receptor (PPAR) and mitogen-activated protein kinase (MAPK) signaling, 
and cell adhesion function (Table 3).  
 
Although it is widely recognized that the mutational profiles of the tumor-related genes differ 
between different tissues, the mechanisms of those organ-specific differences in the mutated 
genes during the process of tumorigenesis remain unclear. We speculated that the genes that 
acquired mutations in HCC tissues might be preferentially and actively transcribed in hepatic 
lineage cells, because it has been shown that AID-induced mutagenic activity is directly 
proportional to the transcription levels of the target gene 35-37. Therefore, we analyzed the gene 
expression profiles in the fetal and adult liver using microarray, and examined whether the 
mutated genes in HCC tissues were transcribed at relatively higher levels in liver-lineage cells 
compared with hematopoietic lineage cells. Among the mutated genes identified, transcription 
levels of 95.4% and 85.8% of the genes in HCC#1 and HCC#2, respectively, were higher in fetal 
and/or adult liver tissues than in bone marrow-derived hematopoietic cells (Table 2, and 
Supplementary Table 4), indicating that the genes actively transcribed in fetal and/or adult liver 
cells might have preferentially acquired the mutations through the genotoxic activity of AID. 
Consistently, quantitative RT-PCR analyses revealed that all the mutated genes analyzed were 
actively transcribed in adult liver tissues (Supplementary Figure 4). In contrast, representative 
genes that are actively transcribed in hematopoietic tissues 38, such as Cd4, Cd5, and Tgfbr2, 
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showed no mutations in liver tumors and less or no transcription in the liver compared with other 
organs (Supplementary Figure 4). We also confirmed that 19 (82.6% in HCC#1) and 93 (88.6% 
in HCC#2) of the mutated genes were actively transcribed in the liver tissues based on the mouse 
whole transcriptome analysis 39.Together, these findings suggest that the acquisition of mutations 




Recently, recognition of the role of tissue stem/progenitor cells in the carcinogenesis process led 
to a new hypothesis that cancer arises from tissue stem/progenitor cells 40. Indeed, 
genetically-engineered fetal progenitor cells lacking the tumor-suppressor gene function have 
been shown to play a role as the origin of liver cancer 9, 11, 41. Whether the stepwise accumulation 
of genetic alterations on hepatic stem/progenitor cells contributes to the development of tumor 
cells, however, remains unknown. In the present study, we demonstrated that engrafted hepatic 
progenitor cells originated from the AID Tg mice progressed to liver tumors, including both 
HCC and cholangiocarcinoma, through the accumulation of somatic mutations in a variety of 
target genes. 
 
Several previous studies demonstrated that the transplanted putative fetal liver stem/progenitor 
cells are capable of repopulating the liver that encounter extensive liver injury favoring the 
proliferation and survival of transplanted hepatocytes 42-44. The DT receptor has been identified 
as a membrane-anchored form of the HB-EGF precursor 26. Recently, it was shown that 
transplanted hepatic progenitor cells derived from the fetal liver were efficiently engrafted and 
repopulated in the liver of recipient HB-EGF-expressing mice with DT stimulation 27, 28. Using 
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this model, efficient engraftment of the transplanted cells in recipient mice with HB-EGF 
expression in the liver enabled us to examine the fate of transplanted hepatic progenitor cells 
with constitutive AID expression. Notably, liver tumors with histologic features of human HCC 
developed in the recipient mice that received the hepatic progenitor cells derived from the AID 
Tg mice, while no tumorigenesis was observed in the recipient mice transplanted with hepatic 
progenitor cells of control mice. The findings that the tumors contained the AID transgene 
indicated that these tumors were derived from the transplanted hepatic progenitor cells 
accompanied with the AID-induced genetic aberrations. Interestingly, one of those tumors 
showed both the characteristics of HCC and cholangiocarcinoma in a single nodule, suggesting 
that the hepatic progenitor cells with the accumulation of genetic aberration could possess the 
potential to progress both HCC- and cholangiocarcinoma- lineage tumor cells. Alternatively, it 
might be possible that AID-mediated genetic alterations contribute to modifying the 
differentiation status of tumor cells, leading to either HCC or bile duct cancers from common 
progenitor cells.  
 
Sequencing of whole genomes, whole exomes, and whole transcriptomes of cancer samples has 
recently become feasible using deep sequencing technologies. In this study, to obtain the overall 
picture of genetic alterations accumulated in the hepatic progenitor cells of the AID Tg mice that 
achieved malignant transformation, we performed whole exome sequencing of the transplanted 
progenitor cells and the resultant tumor tissues, and unveiled the landscape of genetic alterations 
that accumulated during tumorigenesis. We found that various genetic aberrations, mainly SNVs, 
were highly accumulated in the tumors, further supporting the putative involvement of aberrant 
AID activity in the development of HCC. One thing to be noted is that approximately 80% of 
mutated genes detected in the liver cancer tissues developed in the recipient mice have been 
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reported to be mutated in human HCC tissues (International Cancer Genome Consortium; 
http://www.icgc.org/), although it is not possible to draw a definitive conclusion from analyses of 
the limited number of HCCs that developed in the recipient mice. Functional annotation analyses 
revealed that many of the genes that acquired genetic aberrations are categorized into several 
important signaling pathways, including those involved in the regulation of cell proliferation, cell 
metabolism, and cell adhesion. Thus, it could be suggested the stepwise dysregulation of cell 
function caused by the accumulation of genetic aberrations in hepatic progenitor cells appears to 
play a pivotal role in the development of tumor cells.  
 
We previously revealed that genetic changes induced by the genotoxic activity of AID show 
organ-specific profiles and suggested the possibility that the target preference of AID-induced 
mutagenesis contributes to the diversity of tissue-specific oncogenic pathways 23. One possible 
explanation for the target selection for mutagenesis is that AID preferentially induces mutations 
in the actively-transcribed genes in each cell, because AID likely induces somatic mutations on 
the single-strand DNA exposed during the transcription process 35-37. Consistent with this 
hypothesis, we confirmed in this study that the majority of genes with SNVs were the actively 
transcribed genes in liver lineage cells. However, we also observed that the transcription level of 
the gene is not solely responsible for the acquisition of AID-mediated genotoxicity, because one 
of the most actively transcribed hepatotrophic genes, albumin, did not accumulate SNVs in liver 
tumor cells (data not shown). Consistently, extensive sequencing of various genes in B 
lymphocytes revealed that only 25% of the transcribed genes accumulated SNVs in an 
AID-dependent manner 45. Mutational hotspots preferentially attacked by AID genotoxicity 
frequently possess unique sequence characteristics, so-called RGYW/WRCY motifs (where 
W=A or T, R=A or G, and Y=C or T) in transcribed targets 46. Moreover, a recent study reported 
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clusters of various types of repeat sequences in the vicinity of cleaved sites in AID target genes 47. 
Thus, target selection of AID-mediated mutagenesis might require both active transcription and 
sequence characteristics of the genes.  
 
In conclusion, the findings in the present study suggested that mutagenic activity of AID might 
contribute to the malignant transformation of hepatic progenitor cells to liver cancer cells via the 
induction of genetic alterations. Some of the actively transcribed genes in the liver-lineage cells 
preferentially accumulated SNVs and might contribute to the development of tumor cells. 
However, based on the model used in the present study, we could not fully determine whether the 
developed tumors derived directly from the fetal hepatic progenitor cells or via mature 
hepatocytes, because the transplanted fetal progenitor cells differentiated into mature hepatocytes 
in the recipient liver 27. Moreover, the truly significant driver mutations responsible for 
hepatocarcinogenesis remain unclear. Thus, further elucidation of the precise step of the 
AID-induced accumulation of genetic aberrations will be required to identify the genetic 
alterations that possess the key to the carcinogenesis process. In addition, the fractionation by 
fluorescence-activated cell sorting would be essential to identify the subset of hepatic 
stem/progenitor cells that play a role in the origin of tumor cells. 
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Figure 1. Enrichment of hepatic stem/progenitor cells from the fetal liver. 
(A) Schematic diagram showing the transplantation of the enriched hepatic stem/progenitor cells 
of AID Tg mice or control (CTR) mice into the recipient TRECK mice. DT was administered 
intraperitoneally twice a week to recipient (TRECK) mice for 25 wk from the day of cell 
transplantation. The phenotypes were examined 90wk after transplantation. (B) Microscopic 
image (H&E staining) of the fetal liver tissues. Immunohistochemical staining for both the liver 
cell marker albumin and the hematopoietic cell marker CD45 are shown. (C) 
Immunohistochemical staining of the enriched cell population from the fetal liver via sphere 
formation for albumin, AFP, and CD45. (D) Immunohistochemical staining of floating cells that 
did not form spheres for CD45. (E) Representative RT-PCR for the various phenotypic 
expression: albumin, AFP, DLK1, CK19, CD133, CD45 and control Actb (β-actin). Total RNA 
was extracted from the spheres of the enriched cell population from the fetal liver, adult liver 
tissue, bone marrow, and fetal liver tissue. 
 
Figure 2. Efficient engraftment of the transplanted hepatic progenitor cells in the recipient 
liver.  
(A) The hHB-EGF expression in the liver, kidney, and spleen of a TRECK mouse and the liver of 
a wild-type mouse determined by semiquantitative RT-PCR analysis. Upper, hHB-EGF 
expression; Lower, control Actb expression. (B) Immunohistochemical staining for human 
hHB-EGF in the liver of the TRECK and wild-type mice. Upper, hHB-EGF 
immunofluorescence; Lower, DAPI staining. (C) Time-course changes in ALT values of the 
TRECK and wild-type mice after the first DT administration. Vertical bars show SD. (D) 
Immunostaining analysis of liver tissue specimens of a TRECK mouse with (DT [+]) or without 
27 
 
(DT [-]) DT administration. Upper, H&E staining; Middle, E-cadherin immunofluorescence; 
Lower, Ki-67 immunofluorescence. (E) Macroscopic image of a representative liver receiving 
GFP-positive hepatic progenitor cells at 30 days after transplantation. (F) Histologic analysis of 
liver tissue specimens receiving GFP-positive hepatic progenitor cells at 90 days after 
transplantation. Upper, H&E staining; Middle, GFP immunofluorescence; Lower, DAPI staining. 
 
Figure 3. Development of tumors in livers receiving hepatic progenitor cells from AID Tg 
mice. 
(A) Macroscopic images of tumors that developed in recipient mice receiving progenitor cells 
from AID Tg mice. (B) Microscopic images of a liver tumor that developed in a recipient mouse 
receiving hepatic progenitor cells from an AID Tg mouse. Upper, AFP-positive part; Middle, 
CK19-positive part; Lower, non-tumorous liver tissue. Immunohistochemical staining for H&E, 
AFP, and CK19 are shown. (C) Southern blot analysis for the AID transgene. DNA was extracted 
from three liver tumor tissues (Tumor #1, 2, 3), a non-tumor liver tissue (Non-tumor), the kidney 
of the corresponding animal, a liver of a TRECK mouse (Negative control; NC), and a liver of an 
AID Tg mouse (Positive control; PC), followed by the amplification and hybridization to the 
probe specific for the AID transgene. (D) Results of quantitative genomic PCR for AID 
transgene in three liver tumor tissues, a non-tumor liver tissue, and the kidney of the 





Supplementary Materials and Methods 
 
Genome Analyzer sequence data analysis and variant filtering. 
Using the high performance alignment software “NextGENe v2.1“ (SoftGenetics, State 
College, PA), the 76 base-pair reads obtained from the Genome Analyzer IIx were 
aligned with the reference sequences of Mus musculus whole genome derived from the 
NCBI build 37.1 annotation. Reads with 96% or more bases matching a particular 
position of the reference sequences were aligned. Furthermore, two quality filters were 
used for sequencing reads: reads with a median quality value score of more than 20 and 
no more than 3 uncalled nucleotides were allowed anywhere in the 76 bases. Only 
sequences that passed the quality filters, rather than raw sequences, were analyzed and 
each position of the genome was assigned a coverage depth, representing the number of 
times the nucleotide position was sequenced. To identify somatic mutations, we used a 
number of scores developed by SoftGenetics to provide an empirical estimation of the 
likelihood that a given mutation is real and not an artifact of sequencing or alignment 
errors. This score is based on the concept of Phred scores, where quality scores are 
logarithmically linked to error probabilities. The Overall Mutation score is calculated 
according to the following equation: Overall Mutation score = (Coverage score) x (four 
optional scores). The four optional scores are the Read balance score, Allele balance 
score, Mismatch score, and Wrong Allele score. These scores are described in “Next 
GENe v2.1” in detail. The candidates of somatic mutations were selected according to 
the variant filtering process (Supplementary Figure 1). As we further required that 
common variants in mice be excluded, the mutations in liver tumors must not be found 
in more than 5% of the reads in the liver of wild-type C57BL/6 mouse. In addition, the 
mutations in liver tumors should not be observed in the original corresponding hepatic 
progenitor cells of the AID Tg mice, therefore nucleotide alterations could not appear in 
more than 5% of reads in the originating cells. Candidate single nucleotide variants 
were tested using standard Sanger sequencing on an Applied Biosystems 3500 Genetic 
Analyzer (Applied Biosystems, Foster City, CA) to validate the presence of each 
mutation in HCCs and the absence of each in the liver of wild-type mice.  
 
Semiquantitative reverse transcription PCR and quantitative real-time genomic 
and reverse transcription-PCR 
Total RNA was extracted from the tissues using RNeasy Mini Kit (Qiagen). cDNA was 
synthesized using Transcriptor First-Strand cDNA Synthesis Kit (Roche). The 
oligonucleotide primers for the semiquantitative reverse transcription-PCR (RT-PCR) 
are shown in Supplementary Table 1. Quantification of gene copy numbers or gene 
expression was performed by quantitative real-time genomic PCR or RT–PCR using 
LightCycler 480 System II (Roche). The oligonucleotide primers for the quantitative 
real-time genomic PCR and RT-PCR are shown in Supplementary Table 2. To assess the 
quantity of isolated DNA, target DNAs were normalized to the DNA levels of the 
housekeeping reference gene Actb. Similarly, to assess the quality of isolated RNA as 
well as the efficiency of cDNA synthesis, target cDNAs were normalized to the 
endogenous mRNA levels of the housekeeping reference gene 18S rRNA. For simplicity, 
ratios are presented as relative values compared with expression levels in lysate from 
control specimens. 
 
Histology and immunohistochemistry 
The details of the immunohistochemistry procedures were described previously 31-33. 
The primary and secondary antibodies used for immunostaining are shown in 
Supplementary Table 3. 
 
Southern blot analysis 
Southern blot analysis was performed using AlkPhos Direct Labelling Reagents (GE 
Healthcare, Buckinghamshire, England), with DNA probes labeled using alkaline 
phosphatase using the following primer and probe sets: AID transgene SB sense; 
GGACAGCCTTCTGATGAAGC, AID transgene SB antisense; 
TGGCATATGTTGCCAAACTC, AID transgene probe sense; 
GGACAGCCTTCTGATGAAGC, AID transgene probe antisense; 
GAAGTTGTCTGGTTAGCCGG, Actb SB sense; TGTACGTAGCCATCCAG, Actb 
SB antisense; CCTTCACCGTTCCAGT, Actb probe sense; TGAGCTGCCTGACGG, 
Actb probe antisense; GCCACCGATCCACACA. 
 
Statistical analysis 
Statistical differences in the gene expression levels were analyzed using the 
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Supplementary Figure legends 
 
Supplementary Fig 1.  
Variant filtering process for somatic mutations determined by whole exome 
sequencing. 
 
Supplementary Figure 2.  
(A) Immunohistochemical staining for liver tissue derived from ED13.5 fetal mice  
DAPI staining, DLK1 fluorescence and merge. 
(B) Immunohisotochemical staining of the enriched cell population from the fetal liver 
via sphere formation for E-cadherin, DLK1, CK19 and CD133. 
(C) hHB-EGF expression of liver tumor and non-tumor liver tissue. Total RNA was 
extracted from liver tumor tissue (Tumor), non-tumor liver tissue (Non-tumor), kidney 
of the corresponding mouse (Kidney), liver of an AID Tg mouse (Negative control; NC), 
and liver of a TRECK mouse (Positive control; PC), and subjected to semiquantitative 
RT-PCR analysis for hHB-EGF expression. 
(D) Frequency of indels and nucleotide substitution patterns of HCCs. 
 
Supplementary Figure 3.  
Representative Sanger sequencing trace files of Nob1, Pck1 and Mc3r. 
Comparisons of the sequenced regions between the liver of wild-type mouse (Upper) 
and HCC samples from TRECK mice transplanted with hepatic progenitor cells of the 
AID Tg mice (Lower) are shown. Specific mutations are observed in the trace images of 
lower panels and highlighted by the arrows. 
c.: cDNA. p: protein. 
 
Supplementary Figure 4.  
Expression profiles of the representative genes in various tissues of wild-type mice. 
Total RNA was extracted from the liver, kidney, lung, brain and spleen of the wild-type 
mice and subjected to quantitative RT-PCR. The expression levels of the mutated (A) 
and non-mutated (B) genes in the liver cancer tissues are shown. Values shown in the 






Supplementary Table 1. 
Primer sequences used for semiquantitative RT-PCR amplification. 
 
 forward primer reverse primer 
albumin 5’-GACAAGGAAAGCTGCCTGAC-3’ 5’-TTCTGCAAAGTCAGCATTGG-3’ 
AFP 5’-AGCAAAGCTGCGCTCTCTAC-3’ 5’-GAGTTCACAGGGCTTGCTTC-3’ 
DLK1 5’-TGTGACCCCCAGTATGGATT-3’ 5’-CCTTGCAGACTCCATTGACA-3’ 
CK19 5’-CTCGGATTGAGGAGCTGAAC-3’ 5’-TCACGCTCTGGATCTGTGAC-3’ 
CD133 5’-GAAAAGTTGCTCTGCGAACC-3’ 5’-TCTCAAGCTGAAAAGCAGCA-3’ 
CD45 5’-GTGCCTTGTTCAATCTCTTGG-3’ 5’-CAGTTAGCATCCTGCTTGCC-3’ 
hHB-EGF 5’-AGTCCGTGACTTGCAAGAGG-3’ 5’-GTCCCTCTTCTTCCCTAGCC-3’ 

























Supplementary Table 2. 
Primer sequences used for quantitative genomic PCR and RT-PCR amplification. 
 
 forward primer reverse primer 
AID   5'-CGTGGTGAAGAGGAGAGATAGTG-3' 5'-CAGTCTGAGATGTAGCGTAGGAA-3' 
Actb 5’-GTGTGATGGTGGGAATGGGT-3’ 5’-CTGGGTCATCTTTTCACGGTT-3’ 
Sephs2 5’-AAGAGACGGTGCAGGAAGG-3’ 5’-AGTCCATGCCAATGCTCAG-3’ 
Dgat2 5’-AGTGGCAATGCTATCATCATCGT-3’ 5’-AAGGAATAAGTGGGAACCAGATCA-3’ 
Fads2 5’-TCCCTTTCTACGGCATCTTG-3’ 5’-TGTGACCCACACAAACCAGT-3’ 

































Supplementary Table 3. 
Antibodies used for immunostaining. 
 
Primary antibodies  
 
Antigen Species Dilution Supplier 
AFP Rbt 1/200 DAKO 
Albumin Rbt 1/500 Nordic 
CD45 rat 1/500 R&D 
CD133 rat 1/250 eBioscience 
CK19 goat 1/100 Santa Cruz 
DLK1 Rbt 1/150 Abcam 
E-cadherin rat 1/100 Takara 
GFP chicken 1/1000 Abcam 
HB-EGF goat 1/50 R&D 
Ki67 Rbt 1/1000 Novocastra 
 
Secondary antibodies  
 
Conjugate Antigen Species Dilution Supplier 
Alexa Fluor 488 Chicken IgG Goat 1/200 Molecular Probes 
Alexa Fluor 488 Rabbit IgG Goat 1/200 Molecular Probes 
Dylight 488 Goat IgG Donkey 1/100 Jackson 
FITC Rat IgG Donkey 1/100 Jackson 
Dylight 549 Rabbit IgG Donkey 1/200 Jackson 
Dylight 549 Rat IgG Donkey 1/200 Jackson 










Supplementary Table 4. 
List of somatic mutations identified in HCC#1 and HCC#2;  
Gene expression profiles obtained by microarray analysis on the adult liver (AL), 
fetal liver (FL), bone marrow (BM) of wild-type mouse are also shown.    
 
 












Alox12b SNV NS 11 68980425 G>GT 505V>LV 2.38 1.46 
Ccrl1 SNV NS 9 104001408 G>GT 226T>NT 1.98 1.80 
Drd3 SNV NS 16 43762622 A>AT 90E>EV 2.26 1.39 
Erbb2 SNV NS 11 98281423 A>AC 32K>KT 2.12 5.41 
Etv3 SNV S 3 87340528 A>AC 499G>GG 1.35 0.68 
Gpr149 SNV NS 3 62407876 C>AC 208V>FV 2.44 1.43 
Kcnk12 SNV S 17 88145738 C>AC 278L>LL 0.30 0.19 
Mapk8ip3 SNV NS 17 25040950 G>GT 648Y>XY 2.28 1.36 
Mast2 SNV NS 4 115985621 A>AC 686V>VG 2.34 1.44 
Mettl13 SNV NS 1 164474500 T>AT 310E>VE － － 
Myo1d SNV NS 11 80506554 T>GT 44E>ED 2.28 1.45 
Nrap SNV NS 19 56452652 G>GT 331Y>YXY 2.47 1.22 
Olfr30 indel NS 11 58269229 delA;A>AG Frameshift (2.56) (1.55) 
Olfr979 SNV S 9 39808465 A>AC 115T>TT 0.74 0.79 
Prkar1b SNV NS 5 139584476 T>GT 103E>ED 2.34 1.41 
Rnf31 SNV NS 14 56220168 T>TG 882F>LFV 1.20 1.13 
Slc9a9 SNV S 9 94710357 C>CT 182Y>YY 2.39 1.45 
Sorbs1 SNV NS 19 40439589 G>GT 177P>HP 2.93 1.53 
Stk36 SNV NS 1 74670485 A>AG 581T>TA 2.41 1.62 
Tbc1d5 SNV NS 17 50881420 T>AT 655K>NK 1.67 1.09 
Tox3 SNV NS 8 92782013 G>GT 145Y>XY 2.16 1.51 
Ttrap SNV NS 13 24923642 C>CA 15P>TPA 1.13 1.20 
Uhrf1 SNV S 17 56452509 G>GT 300R>RR 0.01 2.19 




        












Aacs SNV S 5 125956363 G>AG 6R>RR 6.42 1.04 
Aacs SNV S 5 125956417 G>AG 24K>KK 6.42 1.04 
Actn1 SNV NS 12 81361038 G>AG 14Q>XQ 0.28 0.27 
Adamts3 SNV NS 5 90204375 C>CT 199V>VI 2.42 1.47 
Ahsg SNV NS 16 22892223 C>CT 13L>LF 7602.86 1829.35 
Ahsg SNV NS 16 22892301 C>CT 39Q>QX 7602.86 1829.35 
Ahsg SNV S 16 22892225 C>AC 13L>LL 7602.86 1829.35 
Akr1c6 SNV NS 13 4435630 G>AG 64A>TA 5080.98 3.94 
Alb SNV NS 5 90889997 C>CT 13S>SF 15204.99 2731.27 
Alb SNV NS 5 90891774 C>CT 63H>HY 15204.99 2731.27 
Apoa1 SNV NS 9 46037935 G>GA 82Q>QHQ 1518.68 158.09 
Apoa1 SNV S 9 46037938 G>AG 83L>LL 1518.68 158.09 
Apoa2 SNV S 1 173155489 C>CT 15S>SS 6878.26 504.23 
Apoe SNV NS 7 20281829 C>CG 279V>VL 12.09 1.25 
Apoe SNV NS 7 20282221 G>AG 148S>FS 12.09 1.25 
Apoe SNV S 7 20282958 C>CT 27Q>QQ 12.09 1.25 
Apof SNV S 10 127706366 G>AG 111Q>QQ 1273.68 53.42 
Apof SNV S 10 127706663 G>AG 210K>KK 1273.68 53.42 
Apon SNV S 10 127691969 C>CT 160N>NN 611.10 1.48 
Arrdc2 SNV NS 8 73363073 C>CT 76S>SN 1.96 3.04 
Aurkaip1 SNV NS 4 155206603 C>CT 67P>PS 1.39 1.39 
Car3 SNV S 3 14864331 G>AG 39K>KK 2182.34 9.80 
Cbx4 SNV S 11 118947307 C>CT 8E>EE 0.80 0.20 
Cd163 SNV S 6 124261711 T>CT 361G>GG 1.88 0.08 
Cebpa SNV S 7 35905297 G>AG 287R>RR 12.28 0.80 
Chka SNV S 19 3852137 C>CT 21S>SS 5.08 2.47 
Creb3l2 SNV NS 6 37391783 C>CT 6S>SN 2.50 1.92 
Creb3l2 SNV S 6 37391785 C>CT 5E>EE 2.50 1.92 
Csnk1g1 SNV S 9 65806460 C>CG 38L>LL 0.30 0.73 
Cspp1 SNV NS 1 10124184 C>AC 1086L>ML 1.05 1.58 
Cyfip2 SNV NS 11 46036116 G>AG 968S>FS 0.10 0.06 
Cyp2e1 SNV NS 7 147950701 G>AG 61A>TA 2536.61 1.43 
Dcn SNV S 10 96957666 C>AC 76P>PP 2.45 1.45 
Dgat2 SNV NS 7 106330954 C>CT 23S>SN 22.46 1.78 
Dnajb11 SNV S 16 22858150 C>CT 13L>LL 1.93 1.58 
Dusp4 SNV S 8 35870934 G>AG 51L>LL 0.20 0.73 
Egr1 SNV NS 18 35021266 G>AG 42S>NS 5.12 7.25 
Egr1 SNV NS 18 35022195 C>CT 126P>PS 5.12 7.25 
Egr1 SNV NS 18 35022756 C>CT 313L>LF 5.12 7.25 
Egr1 SNV S 18 35021216 C>CT 25H>HH 5.12 7.25 
Egr1 SNV S 18 35021181 C>CT 14L>LL 5.12 7.25 
Epha1 SNV NS 6 42315843 G>CG 257L>VL 92.18 16.39 
Espn indel NS 4 151503731 delC;C>CT Frameshift (2.35) (1.45) 
Fabp5 SNV NS 3 10015063 G>AG 58S>NS 1.92 6.34 
Fads2 SNV NS 19 10175779 G>GA 47T>IST 30.86 3.48 
Fgg SNV S 3 82812657 C>CT 131S>SS 9478.53 896.52 
Fos SNV NS 12 86815104 G>AG 39S>NS 0.05 0.03 
Fos SNV S 12 86816132 G>AG 130E>EE 0.05 0.03 
Foxq1 SNV NS 13 31651848 C>CT 355A>AV 3.35 0.77 
Fzd7 SNV S 1 59540012 G>AG 70L>LL 2.51 1.76 
Fzd7 SNV S 1 59540237 G>AG 145R>RR 2.51 1.76 
G0s2 SNV S 1 195098972 G>AG 8S>SS 5.20 0.22 
G0s2 SNV NS 1 195098727 G>AG 90A>VA 5.20 0.22 
G0s2 SNV NS 1 195098751 G>AG 82A>VA 5.20 0.22 
G0s2 SNV NS 1 195098773 C>CG 75A>AP 5.20 0.22 
G0s2 SNV NS 1 195098827 G>AG 57Q>XQ 5.20 0.22 
Gadd45g indel NS 13 51942996 insT;C>CT Frameshift (3.41) (1.15) 
Gdf15 SNV S 8 73155343 C>CT 56E>EE 9.89 3.10 
Gpx1 SNV NS 9 108241856 C>CT 72L>LF 1.58 1.31 
H3f3b SNV S 11 115885064 G>AG 52I>II 0.32 0.75 
Hes1 SNV NS 16 30065775 C>CT 34H>HY 2.79 1.01 
Hes1 SNV NS 16 30066009 G>AG 68D>ND 2.79 1.01 
Hes1 SNV NS 16 30066249 G>AG 69S>NS 2.79 1.01 
Hist1h1c SNV S 13 23831235 C>CT 173S>SS 1.03 1.25 
Hist1h1d SNV NS 13 23647312 C>CT 119P>PS 1.71 2.20 
Hist1h1d SNV NS 13 23647441 C>CT 162P>PS 1.71 2.20 
Hist1h1d SNV NS 13 23647504 C>CT 183P>PSA 1.71 2.20 
Hist1h1d SNV NS 13 23647654 C>CT 233R>RW 1.71 2.20 
Hist1h1e SNV NS 13 23713850 G>AG 193P>SP 0.10 1.73 
Hist1h1e SNV NS 13 23713882 C>CT 182S>SN 0.10 1.73 
Hist1h1e SNV NS 13 23713916 G>AG 171H>YH 0.10 1.73 
Hist1h1e SNV NS 13 23714126 G>AG 101Q>XQ 0.10 1.73 
Hist1h1e SNV S 13 23713857 G>AG 190S>SS 0.10 1.73 
Hist1h2bb SNV NS 13 23838810 C>CT 50H>HY － － 
Hist1h2bk SNV S 13 22128073 C>CT 107L>LL 0.92 1.99 
Hist1h3a SNV NS 13 23853962 C>CT 98S>SN 0.21 1.73 
Hist1h3a SNV S 13 23853961 G>AG 98S>SS 0.21 1.73 
Hist1h4c SNV NS 13 23790295 C>CT 8G>VGD － － 
Hist2h2ac SNV S 3 96024476 C>CT 97L>LL 0.12 1.36 
Hist2h2ac SNV S 3 96024488 C>CT 93E>EE 0.12 1.36 
Hist4h4 SNV NS 6 136752629 G>AG 91L>FL 2.34 1.43 
Hnrnpa1 SNV NS 15 103071540 C>CT 16L>LF 0.27 0.66 
Ier2 SNV S 8 87186325 G>GT 142R>RR 1.68 0.97 
Ier2 SNV S 8 87186580 G>AG 57C>CC 1.68 0.97 
Ier5 SNV NS 1 156945649 G>AG 373P>SP 0.17 0.47 
Igfbp1 SNV NS 11 7098022 G>GA 21G>DAG 770.63 659.29 
Igfbp1 SNV S 11 7098110 C>CT 50C>CC 770.63 659.29 
Il17rc SNV NS 6 113432885 G>AG 600V>MV 77.84 10.63 
Insig1 SNV S 5 28398081 C>CT 35G>GG 36.23 3.07 
Insig1 SNV S 5 28398246 G>AG 90Q>QQ 36.23 3.07 
Insig1 SNV NS 5 28398015 C>CT 13S>RSS 36.23 3.07 
Insig1 SNV NS 5 28398158 G>AG 61S>NS 36.23 3.07 
Insig1 SNV NS 5 28398323 G>AG 116G>DG 36.23 3.07 
Insig1 SNV NS 5 28398328 G>AG 118A>TA 36.23 3.07 
Irf2bp1 SNV NS 7 19589817 G>AG 11W>XW 0.84 1.04 
Jun SNV S 4 94717641 C>CT 424Q>QQ 6.15 2.60 
Jun SNV S 4 94717644 C>CT 423E>EE 6.15 2.60 
Jun SNV S 4 94717991 G>AG 308L>LL 6.15 2.60 
Junb SNV S 8 87501936 C>CG 237G>GG 0.50 0.30 
Junb SNV NS 8 87501814 C>CT 278W>WX 0.50 0.30 
Junb SNV NS 8 87502211 C>CT 146G>GS 0.50 0.30 
Jund SNV S 8 73223213 G>AG 86G>GG 1.52 1.11 
Jund SNV NS 8 73223881 G>AG 309S>NS 1.52 1.11 
Jund SNV NS 8 73223175 G>AG 74A>TA 1.52 1.11 
Klhl13 SNV NS X 22797884 C>CT 508R>RQ 2.46 1.46 
Krt8 SNV S 15 101834373 C>CT 99E>EE 899.20 213.93 
Krt8 SNV S 15 101834421 C>CT 83K>KK 899.20 213.93 
Ldlr SNV S 9 21528266 C>CT 16L>LL 12.26 2.57 
Maob SNV S X 16293534 G>AG 404P>PP 2.57 1.75 
Mc3r SNV NS 2 172074866 G>AG 170V>IV 2.54 1.65 
Mettl7b SNV S 10 128397538 G>AG 152S>SS 725.01 1.49 
Mov10l1 SNV NS 15 88835831 G>AG 514A>TA 2.35 1.45 
Mtf1 SNV S 4 124482127 G>AG 58L>LL 2.36 1.46 
Nfkbia SNV S 12 56593306 C>CT 69Q>QQ 0.58 0.13 
Nkapl SNV S 13 21560171 C>CG 62R>RP 2.46 2.04 
Nr0b2 SNV S 4 133109875 C>CT 179N>NN 25.83 1.43 
Nr0b2 SNV NS 4 133109616 G>AG 93C>YC 25.83 1.43 
Nr0b2 SNV NS 4 133109619 G>AG 94C>YC 25.83 1.43 
Nt5e SNV S 9 88222612 G>AG 30E>EE 2.37 1.45 
Olfr395 SNV NS 11 73720101 C>CT 297M>MI 2.47 1.49 
Olfr750 SNV NS 14 51690384 C>AC 228V>FV － － 
Onecut1 SNV S 9 74710870 G>AG 256L>LL 65.68 20.36 
P4hb SNV NS 11 120434054 C>CT 23E>EK 6.33 1.57 
Paqr9 SNV NS 9 95460521 C>CT 49P>PS 10.09 1.27 
Pck1 SNV NS 2 172979068 G>AG 60M>IM － － 
Pck1 SNV NS 2 172979479 G>AG 90S>NS － － 
Pck1 SNV NS 2 172980228 G>AG 145S>NS － － 
Pcsk9 SNV S 4 106136386 C>CT 43E>EE 87.60 104.05 
Pdzk1 SNV NS 3 96658479 A>AG 162N>ND 60.18 7.95 
Plk2 SNV S 13 111186500 G>AG 129E>EE 8.10 5.19 
Plk3 SNV S 4 116805814 G>AG 139F>FF 14.32 1.57 
Plk3 SNV S 4 116805856 G>AG 125R>RR 14.32 1.57 
Plk3 SNV S 4 116805898 C>CT 111E>EE 14.32 1.57 
Ptma SNV S 1 88426050 G>AG 46E>EE 0.28 1.28 
Qsox1 SNV S 1 157630652 G>AG 343Y>YY 19.30 0.79 
Rac3 SNV S 11 120583903 C>CT 63D>DD 2.20 1.61 
Rbp4 SNV NS 19 38198851 G>AG 61A>VA 9360.58 3515.97 
Rbp4 SNV NS 19 38198896 G>AG 46A>VA 9360.58 3515.97 
Rbp4 SNV S 19 38198853 G>AG 60I>II 9360.58 3515.97 
Rdh8 SNV S 9 20627811 C>CT 110S>SS 2.35 1.43 
Rrs1 SNV NS 1 9536104 G>CG 167M>IM 1.08 2.80 
Scd1 SNV NS 19 44481883 G>GT 6L>IL 318.00 0.95 
Sephs2 SNV S 7 134416519 G>AG 352L>LL 20.37 1.89 
Sephs2 SNV NS 7 134417076 G>AG 166A>VA 20.37 1.89 
Sgk1 SNV NS 10 21714771 C>CT 26A>AV 2.47 1.47 
Sik1 SNV S 17 31991940 C>CT 18Q>QQ － － 
Slc27a2 SNV NS 2 126379128 C>CT 80T>TI 15.48 1.51 
Slc7a5 SNV S 8 124431107 C>CT 133K>KK 0.04 1.42 
Smg1 SNV NS 7 125309982 T>GT 1910K>KN － － 
Socs3 SNV S 11 117829254 C>AC 126V>VV 0.36 1.19 
Sox9 SNV NS 11 112644154 G>AG 86W>XW 17.49 1.93 
St3gal6 SNV NS 16 58473929 C>CT 152G>GD 0.05 0.56 
Tk1 SNV NS 11 117687088 C>CT 2S>SN 0.22 0.92 
Tkt SNV S 14 31362521 C>CT 21R>RR 0.50 0.61 
Tmem49 SNV NS 11 86400004 G>AG 357T>IT 2.80 1.31 
Tob2 SNV S 15 81681801 C>CT 167Q>QQ 2.50 1.30 
Ttr SNV NS 18 20825069 G>AG 61W>XW 291.13 37.23 
Zfp36 SNV S 7 29163230 C>CT 102R>RR 1.75 0.18 
Zfp36 SNV NS 7 29163204 C>CT 111R>RH 1.75 0.18 
Zfp36 SNV NS 7 29163274 C>CT 88A>AT 1.75 0.18 
Zfp36l2 SNV S 17 84586208 C>CT 113A>AA 1.21 0.94 
Zp2 SNV NS 7 127278692 G>AG 549A>VA 2.49 1.49 
 
# NS: nonsynonymous S: synonymous 
 
*Values are expression ratio of adult liver (AL) relative to bone marrow (BM). 
** Values are expression ratio of fetal liver (FL) relative to BM. 
 
The genes which have been reported to be mutated in human HCC tissues are marked with 
half-tone dot meshing. 
 
 
 
 
 
 
 
